Literature DB >> 19172414

Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.

María Susana Mallea-Gil1, Carolina Cristina, María Inés Perez-Millan, Ana M Rodriguez Villafañe, Carolina Ballarino, Graciela Stalldecker, Damasia Becu-Villalobos.   

Abstract

The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergoline with reduction of prolactin levels and shrinkage of tumor burden for at least 36 months. Thereafter, prolactin levels and tumor size increased even though cabergoline dosage was increased. Transcraneal surgery was performed at 56 months of treatment. Prolactin levels and tumor proliferation did not subside and the patient died 14 months later. High GH and IGF-I levels were observed in the late stages of tumor development, with no evidence of acromegalic features. Immunohistochemistry of the excised tumor revealed strong immunoreactivity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19172414     DOI: 10.1007/s12022-009-9057-3

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  37 in total

1.  Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.

Authors:  D McCall; S J Hunter; R S Cooke; B Herron; B Sheridan; A B Atkinson
Journal:  Clin Endocrinol (Oxf)       Date:  2007-01       Impact factor: 3.478

2.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor.

Authors:  S Basu; J A Nagy; S Pal; E Vasile; I A Eckelhoefer; V S Bliss; E J Manseau; P S Dasgupta; H F Dvorak; D Mukhopadhyay
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

3.  Late development of resistance to bromocriptine in a patient with macroprolactinoma.

Authors:  E Delgrange; J Crabbé; J Donckier
Journal:  Horm Res       Date:  1998

4.  Microadenomas of the human pituitary and their vascularization.

Authors:  W Gorczyca; J Hardy
Journal:  Neurosurgery       Date:  1988-01       Impact factor: 4.654

5.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

6.  Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas.

Authors:  Kyongsong Kim; Daizo Yoshida; Akira Teramoto
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

7.  Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.

Authors:  L Caccavelli; I Morange-Ramos; C Kordon; P Jaquet; A Enjalbert
Journal:  J Neuroendocrinol       Date:  1996-10       Impact factor: 3.627

8.  Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat.

Authors:  Slawomir A Mucha; Gabriela Meleń-Mucha; Andrzej Godlewski; Henryk Stepień
Journal:  Virchows Arch       Date:  2007-01-18       Impact factor: 4.064

9.  Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases.

Authors:  Thomas A Gaffey; Bernd W Scheithauer; Ricardo V Lloyd; Peter C Burger; Peter Robbins; Forouzandeh Fereidooni; Eva Horvath; Kalman Kovacs; Takao Kuroki; William F Young; Thomas J Sebo; Darren L Riehle; Allan J Belzberg
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

10.  Morphological evidence for the presence of arteries in human prolactinomas.

Authors:  J Schechter; P Goldsmith; C Wilson; R Weiner
Journal:  J Clin Endocrinol Metab       Date:  1988-10       Impact factor: 5.958

View more
  8 in total

1.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

2.  Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2012-06-14       Impact factor: 4.736

Review 3.  Developmental and Functional Effects of Steroid Hormones on the Neuroendocrine Axis and Spinal Cord.

Authors:  L Zubeldia-Brenner; C E Roselli; S E Recabarren; M C Gonzalez Deniselle; H E Lara
Journal:  J Neuroendocrinol       Date:  2016-07       Impact factor: 3.627

Review 4.  Management of medically refractory prolactinoma.

Authors:  Mark E Molitch
Journal:  J Neurooncol       Date:  2013-10-22       Impact factor: 4.130

Review 5.  Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.

Authors:  Carolina Cristina; Guillermina María Luque; Gianina Demarchi; Felicitas Lopez Vicchi; Lautaro Zubeldia-Brenner; Maria Ines Perez Millan; Sofia Perrone; Ana Maria Ornstein; Isabel M Lacau-Mengido; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Int J Endocrinol       Date:  2014-11-18       Impact factor: 3.257

Review 6.  Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Authors:  Claudia Pivonello; Roberta Patalano; Mariarosaria Negri; Rosa Pirchio; Annamaria Colao; Rosario Pivonello; Renata Simona Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

7.  Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.

Authors:  Gianina Demarchi; Sofía Perrone; Gaela Esper Romero; Cristian De Bonis; Juan Pablo Casasco; Gustavo Sevlever; Silvia Ines Berner; Carolina Cristina
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-19       Impact factor: 6.055

8.  Macroprolactinoma causing VI, X, XII cranial nerve palsies nearly 30 years after initial treatment.

Authors:  Anne de Bray; Zaki K Hassan-Smith; Jamal Dirie; Edward Littleton; Swarupsinh Chavda; John Ayuk; Paul Sanghera; Niki Karavitaki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-07-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.